lifestance health group inc - LFST
LFST
Close Chg Chg %
7.13 -0.08 -1.05%
Open Market
7.06
-0.08 (1.05%)
Volume: 51.46K
Last Updated:
Dec 31, 2025, 10:25 AM EDT
Company Overview: lifestance health group inc - LFST
LFST Key Data
| Open $7.13 | Day Range 7.05 - 7.19 |
| 52 Week Range 3.74 - 8.30 | Market Cap $2.77B |
| Shares Outstanding 389.00M | Public Float 160.23M |
| Beta 1.12 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.02 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.31M |
LFST Performance
| 1 Week | 0.00% | ||
| 1 Month | 9.69% | ||
| 3 Months | 29.40% | ||
| 1 Year | -3.26% | ||
| 5 Years | N/A |
LFST Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About lifestance health group inc - LFST
Lifestance Health Group, Inc. provides outpatient mental health services. It offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. The firm operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. The company was founded by Michael K. Lester, Gwen H. Booth and Danish J. Qureshi in 2017 and is headquartered in Scottsdale, AZ.
LFST At a Glance
Lifestance Health Group, Inc.
4800 North Scottsdale Road
Scottsdale, Arizona 85251
| Phone | 1-602-767-2100 | Revenue | 1.25B | |
| Industry | Medical/Nursing Services | Net Income | -57,443,000.00 | |
| Sector | Health Services | 2024 Sales Growth | 18.501% | |
| Fiscal Year-end | 12 / 2025 | Employees | 10,218 | |
| View SEC Filings |
LFST Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.234 |
| Price to Book Ratio | 1.95 |
| Price to Cash Flow Ratio | 26.05 |
| Enterprise Value to EBITDA | 77.174 |
| Enterprise Value to Sales | 2.498 |
| Total Debt to Enterprise Value | 0.155 |
LFST Efficiency
| Revenue/Employee | 122,428.068 |
| Income Per Employee | -5,621.746 |
| Receivables Turnover | 9.475 |
| Total Asset Turnover | 0.561 |
LFST Liquidity
| Current Ratio | 1.365 |
| Quick Ratio | 1.365 |
| Cash Ratio | 0.675 |
LFST Profitability
| Gross Margin | 26.495 |
| Operating Margin | -2.435 |
| Pretax Margin | -4.605 |
| Net Margin | -4.592 |
| Return on Assets | -2.576 |
| Return on Equity | -3.996 |
| Return on Total Capital | -2.974 |
| Return on Invested Capital | -3.051 |
LFST Capital Structure
| Total Debt to Total Equity | 33.547 |
| Total Debt to Total Capital | 25.12 |
| Total Debt to Total Assets | 21.786 |
| Long-Term Debt to Equity | 29.627 |
| Long-Term Debt to Total Capital | 22.185 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Lifestance Health Group Inc - LFST
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 667.51M | 859.54M | 1.06B | 1.25B | |
Sales Growth
| +76.96% | +28.77% | +22.82% | +18.50% | |
Cost of Goods Sold (COGS) incl D&A
| 520.14M | 691.72M | 834.01M | 919.52M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 54.14M | 69.20M | 80.44M | 70.95M | |
Depreciation
| 15.09M | 28.92M | 37.37M | 40.68M | |
Amortization of Intangibles
| 39.04M | 40.28M | 43.06M | 30.27M | |
COGS Growth
| - | +32.99% | +20.57% | +10.25% | |
Gross Income
| 147.37M | 167.82M | 221.66M | 331.45M | |
Gross Income Growth
| - | +13.87% | +32.08% | +49.53% | |
Gross Profit Margin
| +22.08% | +19.52% | +21.00% | +26.50% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 430.54M | 373.90M | 409.01M | 361.91M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 430.54M | 373.90M | 409.01M | 361.91M | |
SGA Growth
| +30.18% | -13.16% | +9.39% | -11.52% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 23.96M | 18.45M | 48.94M | 1.85M | |
EBIT after Unusual Expense
| (307.13M) | (224.53M) | (236.29M) | (32.31M) | |
Non Operating Income/Expense
| (1.47M) | 633.00K | 50.92M | 1.23M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 24.51M | 8.83M | 21.22M | 26.54M | |
Interest Expense Growth
| +10.75% | -63.98% | +140.37% | +25.05% | |
Gross Interest Expense
| 24.51M | 8.83M | 21.22M | 26.54M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (333.11M) | (232.73M) | (206.58M) | (57.61M) | |
Pretax Income Growth
| -650.05% | +30.13% | +11.23% | +72.11% | |
Pretax Margin
| -49.90% | -27.08% | -19.57% | -4.61% | |
Income Tax
| (25.91M) | (17.17M) | (20.32M) | (170.00K) | |
Income Tax - Current - Domestic
| 977.00K | (433.00K) | 1.59M | 788.00K | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (26.89M) | (16.73M) | (21.91M) | (958.00K) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (307.20M) | (215.56M) | (186.26M) | (57.44M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (307.20M) | (215.56M) | (186.26M) | (57.44M) | |
Net Income Growth
| -706.93% | +29.83% | +13.59% | +69.16% | |
Net Margin Growth
| -46.02% | -25.08% | -17.64% | -4.59% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (307.20M) | (215.56M) | (186.26M) | (57.44M) | |
Preferred Dividends
| - | - | - | 36.75M | - |
Net Income Available to Common
| (343.95M) | (215.56M) | (186.26M) | (57.44M) | |
EPS (Basic)
| -1.0502 | -0.6068 | -0.5069 | -0.1515 | |
EPS (Basic) Growth
| -26.04% | +42.22% | +16.46% | +70.11% | |
Basic Shares Outstanding
| 327.52M | 355.28M | 367.46M | 379.15M | |
EPS (Diluted)
| -1.0502 | -0.6068 | -0.5069 | -0.1515 | |
EPS (Diluted) Growth
| -26.04% | +42.22% | +16.46% | +70.11% | |
Diluted Shares Outstanding
| 327.52M | 355.28M | 367.46M | 379.15M | |
EBITDA
| (229.03M) | (136.88M) | (106.91M) | 40.49M | |
EBITDA Growth
| -592.74% | +40.23% | +21.90% | +137.87% | |
EBITDA Margin
| -34.31% | -15.93% | -10.13% | +3.24% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 8.444 | |
| Number of Ratings | 10 | Current Quarters Estimate | 0.005 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 0.044 | |
| Last Quarter’s Earnings | N/A | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.004 | Next Fiscal Year Estimate | 0.12 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 6 | 2 |
| Mean Estimate | 0.01 | 0.01 | 0.04 | 0.12 |
| High Estimates | 0.01 | 0.01 | 0.07 | 0.18 |
| Low Estimate | 0.00 | 0.01 | 0.01 | 0.06 |
| Coefficient of Variance | 115.48 | 0.00 | 54.76 | 70.68 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 8 |
| OVERWEIGHT | 1 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Lifestance Health Group Inc - LFST
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Lifestance Health Group Inc - LFST
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 13, 2025 | Kenneth A. Burdick Director | 3,416,571 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.31 per share | 14,725,421.01 |
| Aug 13, 2025 | Kenneth A. Burdick Director | 3,417,991 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.35 per share | 14,868,260.85 |
| Aug 13, 2025 | Kenneth A. Burdick Director | 3,436,571 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.54 per share | 15,602,032.34 |
| Aug 13, 2025 | Kenneth A. Burdick Director | 46,511 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.3 per share | 199,997.30 |
| Aug 13, 2025 | Kenneth A. Burdick Director | 3,414,771 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.36 per share | 14,888,401.56 |
| Apr 4, 2025 | Pablo Garcia Pantaleoni Chief Digital Officer | 927,923 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.63 per share | 6,152,129.49 |
| Apr 4, 2025 | Ryan B. Pardo See Remarks | 928,015 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.63 per share | 6,152,739.45 |
| Mar 11, 2025 | Lisa K. Miller See Remarks | 358,655 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.88 per share | 2,826,201.40 |
| Mar 11, 2025 | Lisa K. Miller See Remarks | 365,086 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Ryan B. Pardo See Remarks | 841,733 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.88 per share | 6,632,856.04 |
| Mar 11, 2025 | Ryan B. Pardo See Remarks | 883,342 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Ryan B. Pardo See Remarks | 869,671 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.59 per share | 6,600,802.89 |
| Mar 11, 2025 | Ryan B. Pardo See Remarks | 965,546 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Ryan B. Pardo See Remarks | 937,392 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.59 per share | 7,114,805.28 |
| Mar 11, 2025 | David Patrick Bourdon Chief Executive Officer; Director | 782,841 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | David Patrick Bourdon Chief Executive Officer; Director | 766,074 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.88 per share | 6,036,663.12 |
| Mar 11, 2025 | David Patrick Bourdon Chief Executive Officer; Director | 846,980 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | David Patrick Bourdon Chief Executive Officer; Director | 817,295 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.59 per share | 6,203,269.05 |
| Mar 11, 2025 | David Patrick Bourdon Chief Executive Officer; Director | 941,939 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Ujjwal Ramtekkar Chief Medical Officer | 133,781 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.59 per share | 1,015,397.79 |